Mr Chad E. Davis > Dechert LLP > Boston, United States > Lawyer Profile

Dechert LLP
ONE INTERNATIONAL PLACE
40TH FLOOR, 100 OLIVER STREET
BOSTON, MA 02110-2605
United States
Chad E. Davis photo

Work Department

Intellectual Property

Career

Dr. Chad E. Davis counsels companies, investors, and entrepreneurs on intellectual property matters, especially patent matters. Dr. Davis has extensive experience in prosecution and strategic development of worldwide patent portfolios, intellectual property due diligence, risk assessment through, for example, validity and infringement analyses, post-grant patent proceedings, and intellectual property contracts.

Dr. Davis represents clients in a diverse range of technologies, including pharmaceuticals, drug delivery technologies, crystal forms, organic dyes, chemical processes, polymers, proteins, antibodies, stem cell technology, medical diagnostics, medical imaging, microfluidic devices, adhesives, analytical chemistry, foams, cosmetics, and optical technologies.  For companies developing pharmaceuticals, Dr. Davis provides counsel through all aspects of the business cycle with particular acumen for developing and implementing strategies to maximize worldwide patent and regulatory exclusivities for the pharmaceutical product.

Memberships

American Chemical Society; American Intellectual Property Law Association; Intellectual Property Owners Association

Education

Ball State University, B.S., 1998, summa cum laude; University of Illinois at Urbana-Champaign, Ph.D., Chemistry, 2003; Boston College Law School, J.D., 2007

Lawyer Rankings

United States > Industry focus > Healthcare: life sciences

The ‘highly creative’ practice at Dechert LLP is co-headed by Andrea L C Reid in Boston and David S Rosenthal in New York, who focus on IP and corporate work respectively. Reid advised clinical-stage biopharmaceutical company PureTech Health on IP-related aspects of its deal with Hoffman-La Roche to advance its milk-derived exosome platform technology for the oral administration of Roche’s antisense oligonucleotide platform. Rosenthal has assisted Egalet with an asset purchase agreement to acquire four FDA-approved, non-narcotic pain products from Iroko. Product liability litigators Sheila Birnbaum and Mark Cheffo, who joined the New York office from Quinn Emanuel Urquhart & Sullivan, LLP in July 2018, have been acting for Purdue in over 1,400 cases related to its prescription opioid pain medications. Patent specialist Chad Davis from Goodwin is another recent arrival in Boston. The ‘incredibleCarl Morales in New York, who is experienced in developing and prosecuting patent portfolios for FDA-approved or soon-to-be approved drug products, is also recommended.